Endotoxin limit bacterial

The bacterial endotoxin limit for WFI does not exceed 0.25 USP endotoxin units per ml. The microbial action limit is not greater than 10CFU/100 ml. 

In addition, other tests specific to the drug substance and formulation may apply, such as sterility, microbial limits, bacterial endotoxin, and pH. These types of tests would also be called for in order to comply with local pharmacopoeial requirements. Tests for subvisible particles beyond what is required in the pharmacopoeia may also be necessary due to immunogenicity concerns [29]. 

However, the limit should be even lower a patient receives 60 L of water per dialysis treatment. A treatment lasts for 3 h. That means an intravenous administration of 20 L in 1 h. According to the Ph. Eur. the allowed maximum amount of bacterial endotoxins for parenteral use is 5 lU per kg bodyweight in 1 h. This means for a 60 kg patient that 300 lU bacterial endotoxins are allowed to be present in 20 L resulting in a requirement of <0.015 lU/mL. At this moment the assay technique allows an endotoxin limit of 0.025 lU/ mL to be detected and present water treatment units are able to produce water of this quality. This topic and other requirements are under discussion within the Ph. Eur. committee on dialysis solutions. 

These tests would include compendial tests for Microbial Limits, Sterility, Bacterial Endotoxins, and Antimicrobial Effectiveness. 

Inhibition enhancement validation testing is performed on each raw material and finished product as part of the validation for bacterial endotoxin analysis in accordance with the current USP and the FDA Guidelines. Limits are determined from USP monographs or the FDA Guidelines and are used in calculating the maximum valid dilution (MVD). Serial dilutions are performed of spiked and unspiked product in order to determine the dilution required to overcome inhibition or enhancement (DROIE). If the DROIE does not exceed the MVD, the test is determined to be valid. Confirmation of the DROIE is performed on three finished product or raw material lots in order to complete the product validation. Products are tested at a dilution greater than the DROIE but less than the MVD. 

Bacterial endotoxin kinetic test or gel clot limit standard test method (provide reference number)... 

These impurities pose risks for the safety of proteins used as therapeutics and must be removed to a final concentration below their target limit. In addition, the product stream contacts materials such as filters and resins. Extractables, such as leachates from protein A resins, can pose an immunogenic risk to the patient and must be eliminated.75 Finally, adventitious agents such as viruses and bacterial pathogens or related contaminants such as endotoxins can lead to serious problems with the safety of the protein preparation and therefore must be minimized. Table 32.6 lists concentrations for the above impurities that are generally considered acceptable in a final protein product.76... 

When genetic engineering is used to produce the therapeutic Hb, three challenges present potential limitations to utility. First, the production scale itself presents a significant challenge. A second challenge is related to the expression system and its current limitations and third, bacterial endotoxins or other pyrogens must be removed. 

These tests include compendial tests for microbial limits, sterility, bacterial endotoxins, and antimicrobial effectiveness. 

Two pharmacopoeial limit tests exist. That for pyrogens uses rabbits to assess pharmacological activity and therefore the presence of pyrogens of all kinds. The test for bacterial endotoxins uses lysed amoebocytes (blood cells) of the horseshoe crab and is therefore termed the Limulus amoebocyte lysate (LAL) test. This may be extended to many drug and device products and clearly will be developed in the future to assess the presence of endotoxins in biotechnology products. 

Excipients derived from bacterial transformation or enzymatic processes, such as sugars (e.g., mannitol or dextrose), pose special concerns due to potential contamination by endotoxins. Endotoxins, or pyrogens, are lipopolysaccharides from gram-negative bacteria that can induce severe fever upon parenteral administration. Parenteral products have different limits for allowable endotoxin levels.57... 

Another kind of biotechnological product that is acquiring interest as a therapeutic agent is the biopharmaceuticals derived from plants. As a result of the limited production capacity of many pharmaceutical products, the production in plants represents an innovative tool that can expand the yields of active principles because the large volume of biomass that can be developed at the fields. An extra advantage is that these products are free of human diseases and mammalian viral vectors. In products derived from bacteria, the bacterial endotoxin content of the... 

---